Estrogen therapy and osteoporosis: Principles and practice

American Journal of the Medical Sciences

Volumn 313, Issue 1, 1997, Pages 2-12

  Notelovitz, Morris ^a  

^a Women's Medical and Diagnostic Center   (United States)

Author keywords

Androgen; Calcium; ERT effect on bone cells; Estrogen; Estrogen effect on calcium homeostasis; Exercise; Hormonal therapy; Monitoring ERT; Progestin

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BONE CELL; BONE DENSITY; BONE REMODELING; CALCIUM HOMEOSTASIS; DOSE RESPONSE; ESTROGEN THERAPY; EXERCISE; FEMALE; HIP FRACTURE; HUMAN; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK ASSESSMENT;

EID: 0031032043     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199701000-00002     Document Type: Article

References (121)

1. Albright F, Smith CH, Richardson AM. Postmenopausal osteoporosis, JAMA, 1941;116:2465-74.
2. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estregen. Endocr Rev. 1994;15:275-300.
3. Prince RL. Counterpoint: Estrogen effects on calcitropic hormones and calcium homeostasis, Endocr Rev. 1994;15:301-9.
4. Majeska RJ, Ryaby JT, Einhorn TA. Direct modulation of osteoblastic activity with estrogen. J Bone Joint Surg Am. 1994;76-A;713-21.
5. Chow JW, Lean JM, Chambers TJ. 17-beta estradiol stimulates bone formation in female rats. Endocrinology, 1992;130:3025-82.
6. Nielsen HK, Brixen K, Bouillon B, Moskilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab, 1990;70:1431-7.
7. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science. 1988;241:84-6.
8. Tuppurainen M, Kroger H, Saaikoski S, et al. The effect of gynecological risk factors on lumbar and femoral bone mineral density in peri and postmenopausal women. Maturitas. 1995;21:137-45.
9. Lloyd T, Myers C, Buchanan JC, Demers LM, Collegiate women athletes with irregular menstruation during adolescence have decreased bone density. Obstet Gynecol. 1988; 72:639-42.
10. Prior JC, Vigna YM, Schecter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med. 1991; 323:1221-7.
11. Seeman E, Hooper JL, Bach LA, et al. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989;320:554-8.
12. Matkovic Y, Fontana D, Tominac D, et al. Factors that influence peak bone mass formation: A study of calcium balance and the inheritance of bone mass in adolescent females. Am J Clin Nutr, 1990;52:878-88.
13. Pocock NA, Eisman JA, Hooper JL, et al. Genetic determinance of bone mass ia adults: A twin study, J Clin Invest, 1987;80:706-10.
14. Migliaccio S, Newbold RH, Bullock RC, et al. Alterations of maternal estrogen levels during gestation affect the skeleton of female offspring. Endocrinology, 1996; 137:2118-25.
15. Armamento-Villareal R, Villareal DT, Avioli LV, Civitelli R, Estrogen status and heredity are major determinants of postmenopausal bone mass, J Clin Invest. 1992;92:2464-71.
16. Krall EA, Dawsou-Hughes B. Heritable and lifestyle determinants of bone mineral density. J Bone Miner Res. 1993;8:1-9.
17. Slemenda CW, Christran JC, Williams CJ, et al. Genetic determinants of bone mass in adult women; A re-evaluation of the twin model and the potential importance of gene interaction on irritability estimates, J Bone Miner Res. 1991;6:561-7.
18. Frost HM. The mechanistat: A proposed pathogenetic mechanism of osteoporosis and the bone mass effects of mechanical and nonmechanical agents, J Bone Miner Res. 1987;2:73-85.
19. Rodan GA. Perspectives. Mechanical loading, estrogen de- ficiency, and the coupling of bone formation to bone resorption. J Bone Miner Res, 1991;6:527-9.
20. Notelovitz M, Martin D, Tesar R, et al. Estrogen therapy & variable resistance weight training increase the bone mineral in surgically menopausal women. J Bone Miner Res. 1991;6:583-90.
21. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: A comparative study of exercise, calcium supplementation and hormone replacement therapy. N Engl J Med. 1991;325:1189-95.
22. Kohrt WM, Snead DB, Slatopolskye, Birge S. Additive effects of weight-bearing exercise and estrogea on bone mineral density in older women. J Bone Miner Res. 1995; 10:1303-11.
23. Young MM, Mordin BEC. Effects of natural & artificial menopause on plasma and urinary calcium & phosphorous. Lancet. 1967;2:118-20.
24. Gallagher JC, Riggs BL, DeLuca HF. Effects of estrogen on calcium absorption and serum vitamin D metabolites in poutmenopausal osteoporosis. J Clin Endocrinol Metab. 1980;51:1359-63.
25. Prince BL, Schiff I, Neer RM. Effects of transdermal estrogen replacement on parathyroid hormone secretion. J Clin Endocrinol Metab. 1990;71:1284-7.
26. Stock JL, Coderre JA, Mallette CE. Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 1985;61:595-600.
27. Falch JA, Ostebro H, Haug A. Early postmenopausal bone loss is not associated with a decrease in circulating levels of 25-dihydroxyvitamin D, 1-25 dihydroxyvitamin D or vitamin D binding protein. J Clin Endocrinol Metab. 1987;64:838-41.
28. Chetkowski RJ, Meldrum DR, Steingold E, et al. Biologic effects of transdermal estrogen. N Engl J Med, 1986; 314:1815-39.
29. Packer EL, Holloway L, Newhall K, et al. Effects of estrogen on day long circulating calcium, phosphorous, 1,25 dihydroxyvitamin D, and PTH in postmenopausal women. J Bone Miner Res. 1990;5:877-84.
30. Marcus R, Luz Villa M, Cheema M, et al. Effects of conjugated estrogen on the calcitriol response to parathyroid hormone in postmenopausal women. J Clin Endocrinol Metab. 1992;73:413-18.
31. Bikle DD, Halloran BP, Harris ST, Portale AA. Progestin antagonism of estrogen stimulated 1-25 dihydroxyvitamin D levels. J Clin Endocrinol Metab, 1992;75:519-23.
32. 3 in oophorectomized women, J Clin Endocrinol Metab. 1990;71:1288-93.
33. Gallagher JC, Riggs BL, J, et al. Intestinal calcium absorption & serum vitamin D metabolites in normal subjects and osteoporotic patients. J Clin Invest. 1979;64:729-36.
34. Nordin BEC, Need AG, Morris HA, et al. Evidence for renal calcium leak in postmenopausal women. J Clin Endocrinol Metab. 1991;72:401-7.
35. Wild RA. Estrogen effects on the cardiovascular tree, Obstet Gynecol. 1996;87:27S-35S.
36. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994:140:256-61.
37. Cummings SR, Black RM, Rubin SM. Lifetime risks of hip, Colle's or vertebral fracture and coronary heart disease in white postmenopausal women. Arch Intern Med. 1989; 149:2445-8.
38. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980;303:1195-8.
39. Lindsay H, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomized women. Lancet. 1980;2:1151-4.
40. Maxim P, Ettingner B, Spitalny GM. Fracture protection provided by long-term estrogen treatment, Osteoporos Int. 1995;5:23-9.
41. Cauley JA, Seely DG, Ensrud K, et al. Hormone replacement therapy (HRT) and fracture risk in elderly women. Ann Intern Med. 1995; 122:9-16.
42. Lindsay R, Hart DM, MacLean A, et al. Bone response to termination of estrogen treatment. Lancet. 1978;1:1325-7.
43. Christiansen C, Christensen MS, Transbol I. Bone mass in menopausal women after withdrawal of vestrogen/estroreplacement therapy, Lancet. 1981;1:459-61.
44. Felsen ET, Zhang Y, Hannan MT, et al. Effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-6.
45. Notelovitz M. Osteoporosis: screening, prevention and management. Fertil Steril. 1903;59:707-25.
46. Seeman E, Melton III LJ, O'Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med. 1983;75:977-83.
47. Slemenda CW, Hui SL, Longcope C, et al. Predictors of bone mass in perimenopausal women; a prospective study of clinical data using photonabsorptiometry. Ann Intern Med. 1990;112:98-101.
48. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of WHO study group. Geneva: World Health organization, (WHO Technical Report Series No. 843; 1994).
49. Melton III LJ, Chao EY, Lane I. Biomechanical aspects of fracture. In: Rigs BL, Melton III LJ: eds. Osteoporosis: Etiology, Diagnosis and Management. New York: Raven Press; 1988:111-21.
50. Melton III LJ, Eddy DM, Johnston Jr CL. Screening for osteoporosis, Ann Intern Med. 1990;112:516-28.
51. Scientific Advisory Board of the National osteoporosis Foundation. Clinical indications for bone mass measurements. J Bone Miner Res, 1988;4:1-28.
52. Delmas PD, Biochemical markers of bone turnover. J Bone Miner Res. 1993;8:S549-S55.
53. Garnero P, Gineyts E, Arbault P, et al. Different effects of bisphosphonate & estrogen therapy on free and peptidebound bone cross-links excretion, J Bone Miner Res, 1995; 10:641-8.
54. Daniloff GY, Hesley RP, Ju J, et al. An immunoassay for deoxpyridinoline - a highly specific marker of bone resorption, J Bone Miner Res. 1993;8(51):5357.
55. Hanson DA, Weis MA, Bollen A-M, et al. A specific immunoassay for monitoring human bone resorption; Quantitation of tvpe I collagen cross-linked N. telopeptides in urine. J Bone Miner Res. 1992;11:1251-8.
56. Reproductive health in perimenopause. Contracept Rep. 1993;4:1-10.
57. Lindsay R, Tohme J, Kanders B, The effect of oral contraceptive use on vertebral bone mass in pre and postmenopausal women. Contraception. 1986;34:333-40.
58. Kritz-Silverstein D, Barrett-Conner E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health. 1993;83:100-2.
59. Kleerekoper M, Brienza RS, Schultz LR, et al. Oral contraceptive use may protect against low bone mass: Henry Ford Hospital osteoporosis Cooperative Research Group. Arch Intern Med, 1991;151:1971-6.
60. Cherney A. Bone sparing properties of oral contraceptives. Am J Obstet Gynecol. 1996;174:15-20.
61. Horsman A, Jones M, Francis H, et al. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med. 1983; 300:1405-7.
62. Riis BJ, Christianson JS, Johanson JS, et al. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab. 1990;70:920-4.
63. DeCree, Lewin R, Ostyn M, Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea. Int J Sports Med. 1988;9:187-92.
64. Kanis J. Treatment of osteoporosis in elderly women. Am J Med. 1995;98(suppl 2A):60-6.
65. Black DM. Why elderly women should be screened and treated to prevent osteoporosis. Am J Med. 1995;98(S):67-75.
66. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990;76:2290-5.
67. Steiger P, Cummings SR, Black DM, et al. Age-related decrease in bone mineral density in women over 65, J Bone Miner Res. 1992;7:625-32.
68. Marx CW, Dailey GE, Cheney C, et al. Do estrogens improve bone density in osteoporotic women over age 65? J Miner Res. 1992;7:1275-9.
69. Geelhard E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture, Aust J Public Health. 1994;18:153-60.
70. Genant H, Lucas J, Weiss S, et al. A clinical study of 0.3, 0.625, 1.25 mg. esterified estrogens (Estratab™) for prevention of postmenopausal osteoporosis. Osteoporos Int. 1996;6(suppl S):228.
71. Christiansen C, Lindsay R, Estrogens, bone loss and preservation. Osteoporos Int. 1990;1:7-13.
72. Ettinger B, Genant HK, Steiger P, Madvig P. Low-dos-age micronized 17-beta estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol. 1992;166:479-88.
73. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984;63:759-63.
74. Christensen MS, Hagen C, Christiansen C, Transbol I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: Placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol. 1982;144:873-9.
75. Genant HK, Baylink DJ, Gallagher JL, et al. Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol. 1990;76:579-84.
76. Hillard TC, Whiteroft SJ, Marsh MS, et at. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int. 1994;4:341-8.
77. Lufkin EG, Wahner BW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med. 1992;117:1-9.
78. Garnett T, Studd J, Watson N, et al. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estrogen, estradiol and estradiol with testosterone pellets. Obstet Gynecol. 1992;79:968-72.
79. Holland EFN, Leather A, Studd JWW. Increase in bone mass in older postmenopausal women with low mineral bone density after one year of percutaneous estradiol implants. Br J Obstet Gynaecol. 1995;102:238-42.
80. Savvas M, Studd JWW, Norman S, et al. Increase in bone mass after one year of percutaneous oestracliol and testosterone implants in postmenopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol. 1992; 99:757-60
81. Colditz GA, Hankiason SE, Hunter DJ, et al. Use of estrogens and progestins and the risk of breast cancer in postmenopausal women, N Engl J Med, 1995;332:1589-93.
82. Slemenda C, Hui SL, Longcope C, Johnston CC. Sex steroids and bone mass: A study of changes about the time of menopause, J Clin Invest. 1987;80:1261-9.
83. Reginster JY, Sarlet N, Deboisy R, et al. Minimal levels of serum estradiol prevent postmenopausai bone loss. Calcif Tissue Int. 1992;51:340-3.
84. Campodarve I, Ulrich U, Bell N, et al. Urinary N, telopeptide of type I collagen monitors bone resorption and may predict change in bone mass of the spine in response to hormone replacement therapy. J Bone Miner Res, 1995;10(suppl 1):182.
85. Panay N, Studd JWW. Do progestogens and progesterone reduce bone loss? Menopause. 1996;3:13-19.
86. Munk-Jensen N, Pors-Nielsen S, Obel EB, Bonne-Ericksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: A double-blind placebo controlled study. British Medical Journal. 1988;296:1150-2.
87. Christianson C, Mis BJ. 17-beta estradiol and continuous norethisterone: A. unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab. 1990; 71:836-41.
88. Williams SE, Frenchek B, Speroff T, L. A study of combined continuous ethinyl estradiol and Norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol. 1990;162:438-48.
89. Grey AR, Cundy TF, Beid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in postmenopausal osteoporosis. Clin Endocrinol. 1994;40:671-7.
90. Lukert BP, Johnson BE, Robinson RG. Oestrogen and progesterone replacement therapy reduces glucorticoid-indueed bone loss. J Bone Miner Res. 1992; 7:1063-9.
91. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis & Rheumatism, 1994; 37:1499-1505.
92. Ip M, Lain K, Yam L, et al. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids, Chest. 1994; 105:172-7.
93. Chen TL, Aronson L, Feldman DL. Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology. 1977; 100:619-28.
94. Prior JC. Progesterone as bone trophic hormone. Endocr Rev. 1990; 11:386-98.
95. Colvard DS, Ericksen EF, Keeling PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA. 1989;86:854-7.
96. Kasperk CH, Wergedal JE, Parley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology, 1989; 124:1576-8.
97. Wild RA, Buehanan JR, Myers C, Demers LM. Declining adrenal androgens: An association with bone loss in aging women. Proc Soc Exp Biol Med. 1987; 186:355-60.
98. Longcope C, Baker RS, Hui SL, Johnston CC. Androgens and estrogen dynamics in women with vertebral crush fractures. Maturitas, 1984;6:309-18.
99. Davidson BJ, Ross RK, Paganinni-Hill A, et al. Total and free estrogens and androgens in postmenopausal women with hip fractures, J Clin Endcrinol Metab. 1982;54:115-20.
100. Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause, obstet Gynecol. 1995; 85:529-37.
101. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:227-36.
102. Honor EK, Williams JK, Adams MR, et al. Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary artery reactivity in cynomolgus monkeys. Menopause. 1996;3:23-6.
103. Ettinger B, Genant HK, Can CE. Low-dosage estrogen combined with calcium prevents postmenopausal bone loss: Results of a three-year study. In: Conn DV, Martin TJ, Meunier PJ; eds. Calcium Regulation and Bone Metabolism: Basic and Clinical Aspects. Amsterdam: Elsevior; 1987:918-22.
104. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. Am J Med. 1991;90:171-8.
105. Friedlander AL, Genant HK, Sadowsky J, et al. A twoyear program of aerobic and weight training enhances bone mineral density of young women. J Bone Miner Res. 1995; 10:574-85.
106. Lohman T, Goings S, Pamenter E, et al. Effects of resistance training on regional and total bone mineral density in premenopausal women: A randomized study, J Bone Miner Res. 1995;10:1015-24.
107. Conroy BP, Kraemer WJ, Maresh CM, et al. Bone mineral density in elite junior Olympic weight lifters, Med Sci Sports Exerc. 1993;25:1103-9.
108. Martin D, Notelovitz M. Effects of aerobic training on bone mineral density of postmenopausal women, J Bone Miner Res. 1993;8:931-6.
109. Cheng MZ, Zaman G, Lanyon LE. Estrogen enhances the stimulation of bone collagen synthesis by loading and exogenous prostacyclin but not prostaglandin E2 in organ cultures of Rat Ulnae. J Bone Miner Res. 1994;9:805-16.
110. Brewer V, Meyer BM, Keele MS, et al. Bole of exercise in prevention of evolutional bone mass. Med Sci Sporte Exerc. 1983;15:445-9.
111. Preisinger E, Alacamlioglu Y, Saradeth T, et al. Forearm bone density and grip strength in women after menopause, with and without estrogen replacement therapy. Maturitas. 1995;21:57-63.
112. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332-4.
113. Rubin SM, Cummings SR, Results of bone densitometry affect women's decisions about taking measure to prevent fractures. Ann Int Med, 1992;116:990-5.
114. Ryan PJ, Harrison R, Black CM, Fogelman L. Compliance with hormone replacement therapy (HRT) after screening for postmenepausal osteoporosis. Br J Obstet Gynaecol. 1992;99:325-8.
115. Rozenberg S, Kroll M, Vandromme J, et al. Effect of bone density evaluation on hormone replacement therapy prescription. Maturitas, 1996;24:57-61.
116. Ferguson KJ, Hoegh. C, Johnson S. oestrogen replacement therapy. A survey a women's knowledge and attitudes, Arch Int Med, 1989;149:133-6.
117. Hahn RG. Compliance consideration with oestrogen replacement: Withdrawal bleeding and other factors. Am J Obstet Gynec. 1089;161:1854-8.
118. Doren M, Reuther G, Minne HW, Sehneider HPG, Superior compliance and efficacy of continuous combined oral estrogen-progestogen therapy in postmenopausal women. Am J Obstet Gynecol. 1995; 173:1446-51.
119. Speroff L. Postmenopausal hormone therapy and breast cancer. Am J Obstet Gynecol. 1996;87:44S-54S.
120. Coope J, Marsh J, Can we improve compliance with longterm ERT? Maturitas. 1902;15:151-4.
121. Cook B, Notelovitz M, Rector C, Krischer JP. An osteoporosis patient education and screening program: Results and implications. Patient Education & Counseling, 1991; 17:135-45.